Aligos Therapeutics, Inc.
ALGS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $42 | $19 | $74 | $37 |
| Short-Term Investments | $57 | $104 | $64 | $20 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $5 | $5 | $5 |
| Total Curr. Assets | $103 | $128 | $143 | $62 |
| Property Plant & Equip (Net) | $6 | $6 | $7 | $7 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $6 | $7 | $7 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $110 | $135 | $151 | $70 |
| Liabilities | – | – | – | – |
| Payables | $5 | $4 | $4 | $3 |
| Short-Term Debt | $4 | $4 | $3 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $1 | $0 | $0 |
| Other Curr. Liab. | $14 | $12 | $11 | $16 |
| Total Curr. Liab. | $22 | $20 | $19 | $22 |
| LT Debt | $3 | $3 | $4 | $5 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $13 | $9 | $11 | $72 |
| Total NC Liab. | $16 | $13 | $15 | $77 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $7 | $8 | $8 |
| Total Liabilities | $38 | $33 | $34 | $99 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$622 | -$591 | -$575 | -$618 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $694 | $692 | $691 | $589 |
| Total Equity | $72 | $102 | $116 | -$29 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $110 | $135 | $151 | $70 |
| Net Debt | -$36 | -$12 | -$66 | -$29 |